Corrigendum to Universal newborn screening: A roadmap for action(Molecular Genetics and Metabolism (2018) 124(3) (177–183)(S1096719218301252)(10.1016/j.ymgme.2018.04.009))

C. P. Howson, B. Cedergren, R. Giugliani, P. Huhtinen, C. D. Padilla, C. S. Palubiak, M. D. Santos, I. V.D. Schwartz, B. L. Therrell, A. Umemoto, J. Wang, X. Zeng, X. Zhao, N. Zhong, E. R.B. McCabe

Research output: Contribution to journalComment/debatepeer-review

Abstract

The authors regret having to ask for corrections on the following errata: 1. In the Latin America section, please remove comma between Latin and America.Overall, in 2014, approximately 67% of births in the region received some degree of NBS, meaning that more than one-third of babies—3.5 million newborns—were receiving no reported screening [49]. When compared to data published in 2007, Latin America has shown a clear improvement in coverage in the past decade [2]. Yet for certain common conditions like PKU, only 46% of babies in the region are currently screened for that serious neurological condition [3]. 2. In the Brazil section, instead of “severe combined immunodeficiency” (which is not screened in the public program), please correct to “hemoglobin disorders” (which is part of the public program) and delete the word “and" at the end of the same sentence.1.a.1. History and current status Brazil is worthy of special note as it is the largest country in the region, accounting for 43% of the total land mass of Latin America and 34% of its population. Dr. Benjamin Schmidt established the first local NBS program for the detection of PKU in the city of São Paulo in 1976 with the help of a parent support group, Associação de Pais e Amigos dos Excepcionais (APAE) [43,45], with this initiative being followed in subsequent years by the establishment of a number of private programs, many of which were conducted on a “fee per service basis” [11]. It wasn't until 1990 that a federal law was approved stating that “The hospitals and other health care facilities for pregnant women, public and private, are mandated to carry out examinations for the diagnosis and treatment of abnormalities in the metabolism of the newborn, as well as provide guidance to parents” ([13], as translated by R. Giugliani). Yet, it took more than ten years before the National Program of Newborn Screening was launched by the Brazilian Ministry of Health in 2001 [11]. The current program, which was established in 2012 and directed and funded centrally by the Ministry of Health with each of the 27 federative units in the country being responsible for the conduct of the program within its population, mandates the screening for six conditions, including biotinidase deficiency (BD), congenital adrenal hyperplasia (CAH), CH, cystic fibrosis (CF), PKU and hemoglobin disorders [39]. In addition to the screening itself, NBS services provided by the program include confirmatory tests, referral for treatment and follow-up when necessary to a NBS reference center via the public health care system, with no direct costs charged to the user [11]. The authors would like to apologise for any inconvenience caused.

Original languageEnglish (US)
Pages (from-to)216-217
Number of pages2
JournalMolecular Genetics and Metabolism
Volume127
Issue number3
DOIs
StatePublished - Jul 2019

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Molecular Biology
  • Genetics
  • Endocrinology

Fingerprint Dive into the research topics of 'Corrigendum to Universal newborn screening: A roadmap for action(Molecular Genetics and Metabolism (2018) 124(3) (177–183)(S1096719218301252)(10.1016/j.ymgme.2018.04.009))'. Together they form a unique fingerprint.

Cite this